barasertib

Drug Overview

Barasertib is an investigational, Targeted Therapy drug that scientists are studying for the treatment of certain types of cancer, especially blood cancers like acute myeloid leukemia (AML). It is considered a “Smart Drug” because it is designed to look for and attack specific parts of cancer cells without harming as many normal cells. Because it is still being tested in clinical trials, it is not yet available at regular pharmacies.

• Generic Name: Barasertib (also known in research as AZD1152)
• US Brand Names: Not applicable (Investigational drug)
• Drug Class: Targeted Therapy / Aurora B Kinase Inhibitor
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Investigational (Not yet approved by the FDA)

What Is It and How Does It Work? (Mechanism of Action)

To understand how barasertib works, it helps to look at how cells grow and divide. When a cell divides to make new cells, it goes through a process called mitosis. During mitosis, a cell copies its DNA (chromosomes) and pulls the copies apart so that each new cell gets a complete set of instructions.

Barasertib is a highly selective Aurora B kinase inhibitor. Aurora B kinase is a special enzyme (a type of protein) that acts like a traffic cop during cell division. It makes sure the chromosomes align correctly and separate evenly. In many cancer cells, there is too much of this enzyme, causing the cells to divide rapidly and out of control.

At the molecular level, barasertib works by:

1. Entering the bloodstream as a prodrug: It is given as a “prodrug,” meaning the body quickly changes it into its active fighting form (called AZD1152-HQPA).
2. Blocking the enzyme: The active drug specifically binds to the Aurora B kinase enzyme and turns it off.
3. Stopping cell division: Without the enzyme working, the cancer cell cannot align its chromosomes correctly. The cell’s “spindle checkpoint” (a safety mechanism) fails.
4. Causing cancer cell death: Because the cell cannot divide its DNA properly, it ends up with the wrong amount of DNA inside. The cancer cell realizes it is broken and goes through a self-destruct process called apoptosis.

FDA-Approved Clinical Indications

Because barasertib is still in the research and clinical trial phase, it does not currently have any FDA-approved clinical indications. However, it is being actively studied for the following conditions.

Oncological Uses (Under Investigation)

• Acute Myeloid Leukemia (AML)
• Advanced solid tumors
• Certain types of lung cancer (Small Cell Lung Cancer)
• Brain tumors (such as Glioblastoma) in laboratory studies

Non-Oncological Uses

• None. This drug is being studied exclusively for cancer treatment.

Dosage and Administration Protocols

Note: Because barasertib is an investigational drug, dosages are based on clinical trial protocols and may vary based on the specific study.

Clinical Efficacy and Research Results

Recent clinical studies (continuing into the 2020-2025 era of research) have looked closely at how well barasertib works, especially for older patients with acute myeloid leukemia (AML) who cannot handle harsh chemotherapy.

• Response Rates: In a key clinical trial comparing barasertib to standard low-dose chemotherapy (LDAC) in elderly AML patients, barasertib showed a significantly higher success rate. About 35.4% of patients taking barasertib had their leukemia completely disappear (objective complete response), compared to only 11.5% of patients taking the standard chemotherapy.
• Survival Data: While the drug helped patients achieve remission faster, the overall survival time showed a median of 8.2 months for patients on barasertib compared to 4.5 months for standard low-dose treatment.
• Modern 2020-2025 Research: Because the 7-day IV infusion requires a long hospital stay, current research is focusing on packing the drug into tiny “nanoparticles.” These nanoparticles slowly release the drug over time, which may improve how well it works and allow patients to be treated at home.

Safety Profile and Side Effects

Because barasertib stops cells from dividing, it can also affect healthy cells that divide quickly, such as normal blood cells and the cells lining the mouth.

Common Side Effects (>10%)

• Stomatitis/Mucosal Inflammation (up to 71%): Painful sores in the mouth and throat.
• Febrile Neutropenia (up to 67%): A dangerous drop in white blood cells accompanied by a high fever.
• Infections (around 73%): Because the immune system is weakened.
• Nausea and Diarrhea (around 46-50%): Stomach upset and loose stools.

Serious Adverse Events

• Severe Bone Marrow Suppression: The drug can severely lower all blood cell counts, increasing the risk of life-threatening bleeding and infections.
• Black Box Warning: As an investigational drug, barasertib does not yet have an official FDA Black Box Warning. However, its severe bone marrow toxicity is a major safety concern noted by all researchers.

Management Strategies

• For Mouth Sores: Patients are given special mouthwashes, ice chips, and pain relievers. Soft, bland diets are highly recommended to prevent irritation.
• For low blood counts, doctors may prescribe growth factor injections to help the bone marrow make new white blood cells. Antibiotics or antifungal medicines are given to prevent or treat infections early.

Connection to Stem Cell and Regenerative Medicine (If Applicable)

Research Areas: While barasertib itself is not a stem cell therapy, researchers are actively looking at how targeted therapies like Aurora B kinase inhibitors affect cancer stem cells. In acute myeloid leukemia (AML), abnormal cancer stem cells hide in the bone marrow and are often responsible for the disease coming back after treatment. Future regenerative medicine and immunotherapy combinations may explore using drugs like barasertib to clear out bulk cancer cells, followed by stem cell rescue or immune system boosters to keep the cancer from returning.

Patient Management and Practical Recommendations

If a patient is enrolled in a clinical trial for barasertib, their healthcare team will monitor them very closely.

Pre-Treatment Tests to be Performed

• Complete Blood Count (CBC) to check white blood cells, red blood cells, and platelets.
• Liver and kidney function blood tests.
• Bone marrow biopsy to check the status of the leukemia.
• Dental check-up (to treat any hidden mouth infections before mouth sores can develop).

Precautions During Treatment

• Patients usually need to stay in the hospital or have specialized home-care nursing for the 7-day continuous IV infusion.
• Frequent temperature checks are required to catch any signs of fever early.

Do’s and Don’ts List

• Do wash your hands often with soap and water to prevent infections.
• Do use a very soft toothbrush to protect your gums and mouth.
• Do report any fever higher than 100.4°F (38°C) or chills to your doctor immediately.
• Don’t eat raw or undercooked meats, seafood, or unwashed fruits, as they can carry dangerous bacteria.
• Don’t take aspirin or ibuprofen without asking your doctor, as these can increase bleeding risks.
• Don’t be around people who are sick, have a cold, or have recently had a live vaccine.

Legal Disclaimer

Standard medical information disclaimer: The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Barasertib is an investigational medication and is not approved by the U.S. Food and Drug Administration (FDA) or other global health authorities for general use outside of clinical trials. Always consult with a qualified healthcare professional or your oncologist regarding diagnosis, treatment options, and enrollment in clinical trials. Do not start, stop, or change any medical treatment based on the information provided here.